MENU
+Compare
BIXT
Stock ticker: OTC
AS OF
May 30 closing price
Price
$0.16
Change
+$0.01 (+6.67%)
Capitalization
11.69M

BIXT Bioxytran, Inc. Forecast, Technical & Fundamental Analysis

Bioxytran Inc is a biopharmaceutical company... Show more

BIXT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BIXT with price predictions
May 30, 2025

BIXT's Stochastic Oscillator remains in overbought zone for 3 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for BIXT crossed bearishly below the 50-day moving average on May 08, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIXT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BIXT entered a downward trend on May 23, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIXT's RSI Oscillator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on May 20, 2025. You may want to consider a long position or call options on BIXT as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BIXT just turned positive on May 21, 2025. Looking at past instances where BIXT's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

BIXT moved above its 50-day moving average on May 30, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIXT advanced for three days, in of 144 cases, the price rose further within the following month. The odds of a continued upward trend are .

BIXT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BIXT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.282). P/E Ratio (0.000) is within average values for comparable stocks, (59.459). BIXT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (270.467).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIXT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BIXT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
75 2nd Avenue
Phone
+1 617 494-1199
Employees
6
Web
https://www.bioxytraninc.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RTIRX11.860.04
+0.34%
Russell Inv Multifactor Intl Eq R6
ZGFAX19.440.03
+0.15%
American Beacon Ninety One Gbl Frnchs Y
GGCIX120.100.09
+0.07%
Gabelli Growth I
VTPSX143.88-0.15
-0.10%
Vanguard Total Intl Stock Idx InstlPls
JCNCX22.87-0.05
-0.22%
Janus Henderson Contrarian C

BIXT and Stocks

Correlation & Price change

A.I.dvisor tells us that BIXT and CCCC have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIXT and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIXT
1D Price
Change %
BIXT100%
+4.51%
CCCC - BIXT
22%
Poorly correlated
-5.30%
IMUX - BIXT
22%
Poorly correlated
-2.97%
WVE - BIXT
20%
Poorly correlated
-3.69%
DOMH - BIXT
20%
Poorly correlated
-3.70%
BSEM - BIXT
11%
Poorly correlated
N/A
More